文献速递眼底病与葡萄膜炎

噻唑烷二酮类与糖尿病眼病发病及进展无纵向关联:ACCORD眼病研究

Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study.
PubMed 文献 · Am J Ophthalmol · 2017-12-22

该研究为ACCORD随机临床试验的辅助队列研究,分析2856例无增殖性糖尿病视网膜病变史参与者的基线与4年随访数据。结果显示,噻唑烷二酮类使用与糖尿病黄斑水肿发病、视网膜病变进展及视力结局无一致关联。

要点

  • 噻唑烷二酮类使用与糖尿病黄斑水肿发病无关联(aOR 1.22,95%CI 0.72-2.05)。
  • 基线无或轻度糖尿病视网膜病变者曾用噻唑烷二酮类者视网膜病变发病/进展更常见(aOR 1.68,95%CI 1.11-2.55),校正用药时间后关联消失(aOR 1.02,95%CI 1.00-1.04)。
  • 噻唑烷二酮类使用对最终视力结局无影响。

核心结论

  • 在2型糖尿病患者的纵向研究中,噻唑烷二酮类使用与视力结局或糖尿病黄斑水肿进展无关联,且与从未使用者相比,曾用噻唑烷二酮类者无一致的糖尿病视网膜病变进展增加证据。

研究设计与样本

  • 随机临床试验的辅助队列研究,分析2856例无增殖性糖尿病视网膜病变史的ACCORD试验参与者的基线和4年随访数据。

主要发现

  • 噻唑烷二酮类使用与糖尿病黄斑水肿发病无关联:任何使用分析aOR 1.22(95%CI 0.72-2.05),使用时长分析aOR 1.02(95%CI 0.99-1.04)。
  • 基线无或轻度糖尿病视网膜病变者中,曾用噻唑烷二酮类者糖尿病视网膜病变发病/进展更常见(aOR 1.68,95%CI 1.11-2.55),但校正噻唑烷二酮类使用时间后该关联消失(aOR 1.02,95%CI 1.00-1.04)。
  • 基线中度或更差糖尿病视网膜病变者中,噻唑烷二酮类使用者与未使用者的糖尿病视网膜病变进展无差异。
  • 噻唑烷二酮类使用对最终视力结局无影响。

关键数值与推荐

  • 糖尿病黄斑水肿发病:任何使用aOR 1.22(95%CI 0.72-2.05),使用时长aOR 1.02(95%CI 0.99-1.04)。
  • 基线无或轻度糖尿病视网膜病变者糖尿病视网膜病变发病/进展:曾用噻唑烷二酮类aOR 1.68(95%CI 1.11-2.55),校正使用时间后aOR 1.02(95%CI 1.00-1.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the longitudinal association between use of thiazolidinediones (TZDs), visual acuity (VA) change, and diabetic eye disease incidence and progression. DESIGN: Cohort study ancillary to a randomized clinical trial. METHODS: We analyzed baseline and 4-year follow-up data of 2856 ACCORD trial participants with no history of proliferative diabetic retinopathy. Based on stereoscopic fundus photographs, we evaluated diabetic macular edema (DME) progression and DR progression. We also evaluated 10- and 15-letter change on the ETDRS visual acuity chart. Main outcome measures were incidence or progression of DME or DR and change in visual acuity. RESULTS: TZD use was not associated with DME incidence in either the analysis of any use (adjusted odds ratio [aOR] [95% CI]: 1.22 [0.72-2.05]) or duration of use (aOR: 1.02 [0.99-1.04]). Diabetic retinopathy (DR) incidence/progression was more common in patients with no or mild DR at baseline who were ever treated with TZDs (aOR: 1.68 [1.11-2.55]), but this association disappeared when adjusting for the time on TZD (aOR: 1.02 [1.00-1.04]). DR progression among those with moderate or worse DR at baseline was no different between TZD users and non-users. TZD usage had no effect on the ultimate visual acuity outcome. CONCLUSION: In this longitudinal study of patients with type 2 diabetes, we found no association between TZD use and visual acuity outcomes or DME progression, and no consistent evidence of increased DR progression in patients ever treated with TZDs vs those never treated with TZDs.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gower EW, Lovato JF, Ambrosius WT, et al. Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. Am J Ophthalmol. 2017. PMID: 29275147. doi:10.1016/j.ajo.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。